Vilma:
Accelerate Diagnostics' trailing-twelve-month ROE is -70.94 percent.
Lelia:
Mettler-Toledo shares have jumped 35.44 percent over the past 52 weeks, while the S&P 500 index has gained 7.75 percent in the same period.
Lin:
Lennox reported better-than-expected Q2 earnings.
Becky:
As always, thank you for your time.
Karin:
Put more simply: shares are relatively expensive.
Shela:
However, with MTD currently trading at 52-week highs and several factors possibly constraining EPS, negative news could send price levels closer to more normal valuations.
Karri:
The market price of MTD has risen significantly the past year or so.
Walter:
Assume a return to normal PE levels of about 21X earnings.
Ozella:
If today's price is too expensive, what might be a reasonable future entry point for this quality company?
Celsa:
So What Might Be An Entry Point for a Patient Value Investor?
Mettler-Toledo International (NYSE:MTD)
//stockhand.net/us/?q=nyse%3Amtd&id=84748
No comments:
Post a Comment